JMP Securities analyst Jason Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and lowers the price target from $106 to $78.
JMP Securities Maintains Market Outperform on Cytokinetics, Lowers Price Target to $78
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.